Core Viewpoint - Solo Brands, Inc. is appealing the NYSE Regulation's decision to delist its Class A common stock due to "abnormally low" price levels, with the aim of restoring compliance with NYSE listing standards [1][2][4]. Group 1: Company Actions and Status - The NYSE Regulation staff determined that Solo Brands' Class A common stock was unsuitable for listing, leading to a trading halt and current quotation on the OTC Pink Market under the symbol "DTCB" [2][3]. - The company plans to continue operating in compliance with SEC regulations and NYSE listing requirements during the appeal period [5]. - If the appeal is successful, trading of the Class A common stock may resume on the NYSE [3]. Group 2: Company Perspective - The interim President and CEO of Solo Brands stated that the current trading price and market capitalization do not reflect the company's value, prompting the appeal [4]. - The company is committed to executing action plans, including a reverse stock split, to restore compliance with NYSE standards [4]. Group 3: Company Overview - Solo Brands is headquartered in Grapevine, TX, and operates a portfolio of lifestyle brands, including Solo Stove, Chubbies, Isle, and Oru, focusing on innovative outdoor and apparel products [6].

Core Viewpoint - Jin Medical International Ltd. has received a deficiency letter from Nasdaq regarding non-compliance with the minimum bid price requirement for its ordinary shares, which must be at least $1.00 per share for continued listing on The Nasdaq Capital Market [1][2]. Compliance Status - The deficiency notice does not immediately affect the listing status of the ordinary shares, and the company has a compliance period of 180 calendar days, until October 29, 2025, to regain compliance [2][3]. - If the closing bid price reaches or exceeds $1.00 for a minimum of 10 consecutive business days before the deadline, the company will be notified of compliance [2]. Reverse Stock Split - The company may implement a reverse stock split to regain compliance, which must be completed no later than ten business days prior to October 29, 2025 [2][4]. - If the company fails to regain compliance within the initial 180-day period, it may be eligible for an additional compliance period, provided it meets other listing requirements [3][4]. Company Overview - Jin Medical International Ltd. was founded in 2006 and is headquartered in Changzhou, Jiangsu Province, China, focusing on designing, developing, manufacturing, and marketing wheelchairs and living aids for people with disabilities and the elderly [5]. - The company operates two manufacturing plants totaling approximately 230,000 square feet and is establishing a new facility of 430,000 square feet in Chuzhou, Anhui Province [5]. - Jin Medical has over 40 distributors in China and more than 20 international distributors, with a significant portion of its wheelchair products sold to Japan and China [5].

Core Points - TransCode Therapeutics has announced a 1-for-28 reverse stock split effective at 12:01 a.m. Eastern Standard Time on May 15, 2025, to increase the per share trading price and meet Nasdaq listing requirements [1][2] - The reverse stock split will reduce the number of outstanding shares from approximately 23,341,336 to about 833,620 shares, with no fractional shares issued [2] - The company's CUSIP number will change to 89357L 501 as of the effective time of the reverse stock split [4] Company Overview - TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics, utilizing its proprietary TTX nanoparticle platform [5] - The lead therapeutic candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker associated with metastasis [5] - The company is also developing a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for cancer treatment [5]

Core Insights - The marijuana sector continues to face significant challenges, leading to a lack of investor interest, particularly as cannabis remains illegal at the federal level in the U.S. [1] - Tilray Brands has experienced a substantial decline in its stock value, losing over 26% in April and trading under $1, indicating a prolonged downward trend [1][4] - The company reported a 1% year-over-year decline in net revenue for fiscal Q3 2025, totaling just under $186 million, and posted a non-GAAP loss of $2.9 million compared to a profit of $885,000 in the same period the previous year [2][4] Financial Performance - Tilray's management has reduced its revenue guidance for 2025, now expecting $850 million to $900 million, down from a previous estimate of $950 million to $1 billion [4] - The company is considering a reverse stock split with a proposed ratio of 1-to-10 to 1-to-20 to boost its stock price, which will be voted on in a special shareholders' meeting on June 10 [5] Diversification Efforts - In an attempt to diversify, Tilray has been acquiring craft breweries, as beer has broader market appeal and is not subject to the same regulatory challenges as cannabis [7] - However, the beer market has also faced challenges, with consumption hitting a four-decade low in 2024, raising doubts about whether this strategy will improve Tilray's fortunes [8] Market Outlook - There are currently no clear catalysts for Tilray's recovery, with the only potential being the decriminalization of cannabis in the U.S., which appears unlikely in the near term [9]

Core Viewpoint - TransCode Therapeutics has announced a 1-for-28 reverse stock split to comply with Nasdaq's minimum bid price requirements, aiming to increase the trading price of its common stock [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert twenty-eight current shares into one new share, reducing the total outstanding shares from approximately 23,341,336 to about 833,620 [2]. - No fractional shares will be issued; instead, stockholders will receive rounding up of fractional shares to the nearest whole number [2]. - Proportional adjustments will be made to the exercise prices of outstanding stock options and warrants, as well as to the shares issued under stock incentive plans [2]. Group 2: Implementation and Process - Vstock Transfer LLC will serve as the exchange agent for the reverse stock split, and stockholders of record will not need to take action to receive their post-split shares [3]. - Stockholders holding shares through banks or brokers will have their positions automatically adjusted, but they may need to check with their respective institutions for specific procedures [3]. - The effective date of the reverse stock split will be announced by the company at least two business days prior to implementation [4]. Group 3: Company Overview - TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics [5]. - The company's lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis [5]. - TransCode is also developing a portfolio of first-in-class RNA therapeutic candidates aimed at overcoming RNA delivery challenges to access novel genetic targets for cancer treatment [5].

Core Viewpoint - Wheels Up Experience Inc. is focused on improving profitability and expanding margins through fleet modernization, partnerships, and premium customer solutions [1][2]. Financial Compliance - Wheels Up received a notice from the NYSE on April 22, 2025, indicating that its average closing stock price was below $1.00 for 30 consecutive trading days, which is necessary for continued listing [1][3]. - The company has six months to regain compliance with the NYSE's minimum share price requirement and plans to seek stockholder approval for a reverse stock split at its annual meeting on June 10, 2025 [3]. Business Strategy - The company is committed to long-term operational improvements and aims to build a resilient business model for sustainable profitability [2]. - Key initiatives include modernizing its fleet with Embraer Phenom 300 and Bombardier Challenger 300 jets, leveraging a partnership with Delta Air Lines, and delivering premium solutions for customers [2]. Financial Position - As of December 31, 2024, Wheels Up had approximately $316 million in liquidity, consisting of about $216 million in unrestricted cash and an undrawn $100 million commitment from Delta [2]. Company Overview - Wheels Up is a leading provider of on-demand private aviation in the U.S., offering a diverse fleet and a global network of safety-vetted charter operators [4]. - The company provides charter and membership programs, as well as freight, safety, security, and managed services to various clients, including individuals and government organizations [4].

Core Points - Atos SE has completed a reverse stock split as decided by its Board of Directors on March 6, 2025, following a delegation of powers by the shareholders' General Meeting on January 31, 2025 [1][2][3] Summary by Sections Reverse Stock Split Details - The reverse stock split is a technical exchange transaction that does not affect the total value of shares held by shareholders [2] - The exchange ratio is 10,000 old shares with a par value of €0.0001 for 1 new share with a par value of €1 [9] - The total number of old shares subject to the reverse stock split was 190,358,728,519, resulting in 19,035,872 new shares [9] Shareholder Actions - Shareholders holding multiples of 10,000 shares do not need to take any action as their shares were automatically consolidated [4] - Shareholders with fractional rights will be compensated by their financial intermediaries within 30 days of April 24, 2025 [5] Adjustments Related to Warrants - The exercise parity of the share subscription warrants issued on December 18, 2024, has been adjusted in accordance with the reverse stock split [6][7] - The new exercise parity corresponds to the product of the previous exercise parity and the ratio of new shares to old shares, resulting in a maximum of 1,107,589 new ordinary shares available upon exercise [7] Adjustments for Free Share Allocations - The rights of beneficiaries of free share allocations have been adjusted to reflect the reverse stock split, with the number of rights allocated being rounded down to the nearest whole number if necessary [10][11] Trading and Timetable - The new shares began trading on Euronext Paris on April 24, 2025, under ISIN code FR001400X2S4 [9][12] - The compensation period for shareholders with fractional rights runs from April 24 to May 25, 2025 [12] Company Overview - Atos is a global leader in digital transformation with approximately 74,000 employees and annual revenue of around €10 billion [13] - The company specializes in cybersecurity, cloud, and high-performance computing, providing tailored solutions across 68 countries [13]

Core Points - Cara Therapeutics, Inc. has announced a 1-for-3 reverse stock split of its outstanding shares of common stock [1] - The company's common stock will begin trading under the new name "Tvardi Therapeutics, Inc." and the new symbol "TVRD" following the merger with Tvard Therapeutics, Inc. [2] - The reverse stock split was approved by stockholders and will reduce the number of outstanding shares from approximately 4.6 million to approximately 1.5 million [3][4] Company Overview - Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases [7] - Cara Therapeutics is a biopharmaceutical company that has developed an IV formulation of difelikefalin for treating moderate-to-severe pruritus associated with advanced kidney disease [8]

Core Viewpoint - Antelope Enterprise Holdings Limited will implement a 1-for-40 reverse stock split of its Class A ordinary shares effective April 4, 2025, to comply with NASDAQ's minimum bid price requirement of $1.00 per share [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will consolidate every 40 issued and outstanding Ordinary Shares into one Ordinary Share, reducing the total number of shares from approximately 41,430,051 to about 1,035,752 [3]. - Shareholders entitled to fractional shares will receive one full share instead of a fractional share [3]. - All outstanding stock options, warrants, and other rights to purchase the Company's Ordinary Shares will be adjusted proportionately due to the reverse stock split [3]. Group 2: Compliance and Listing Requirements - The reverse stock split is aimed at regaining compliance with NASDAQ's requirement that the Company's common stock must have a closing bid price of $1.00 or more for at least ten consecutive trading days by April 30, 2025 [2]. - There is uncertainty regarding whether the Ordinary Shares will remain above the $1.00 minimum bid price after the reverse split, which is crucial for maintaining NASDAQ listing compliance [2]. Group 3: Company Overview - Antelope Enterprise holds a 51% ownership stake in Hainan Kylin Cloud Services Technology Co. Ltd, which operates a livestreaming e-commerce business in China, providing access to over 800,000 hosts and influencers [5].

Core Viewpoint - Ohmyhome Ltd. has announced a reverse stock split of its ordinary shares at a ratio of 1-for-10, aimed at complying with Nasdaq's minimum bid price requirement [1][4]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the total number of outstanding ordinary shares from approximately 24 million to about 2.4 million [2]. - The effective date for the reverse stock split is March 10, 2025, and the new par value of the shares will be adjusted to $0.01 per share [3]. - Outstanding warrants and options will be adjusted proportionately in accordance with the reverse stock split, with no fractional shares issued [5]. Group 2: Compliance and Corporate Actions - The reverse stock split is part of Ohmyhome's strategy to meet Nasdaq's requirement of maintaining a minimum bid price of at least $1.00 per share [4]. - The Company has amended its Memorandum of Association to proportionately reduce the number of authorized shares for issuance [3]. Group 3: Company Overview - Ohmyhome is a property technology platform in Singapore, providing end-to-end property solutions including brokerage, renovation, and property management services [7]. - Since its launch in 2016, Ohmyhome has transacted over 15,500 properties and manages approximately 9,300 units as of October 29, 2024 [7].